Share This Article:

Long Term Progression Free Survival Achieved by Maintenance “Second–Line” Polychemotherapy with Gemcitabine/Paclitaxel in Metastatic Urothelial Cancer of the Renal Pelvis—A Case Report

Abstract Full-Text HTML Download Download as PDF (Size:444KB) PP. 229-231
DOI: 10.4236/jct.2010.14035    4,871 Downloads   8,626 Views  

ABSTRACT

Moderate activity of systemic chemotherapy for advanced urothelial cancer has been reported for more than 30 years. Only with the advent of potent combination therapy clinically significant response rates as well as prolonged survival were documented. The therapeutic effect of a “second-line” polychemotherapy in metastatic upper tract urothelial cancer is largely unknown caused by the small number of cases and poor prognosis. We report an interesting case of a 59-year-old man suffering from urothelial cancer of the renal pelvis with pulmonary, lymphogenic and bone metastases who showed an unexpected response to a “second-line”chemotherapy after only 2 treatment cycles of Gemcitabine/Paclitaxel (partial remission) after 24 treatment cycles Gemcitabine / Cisplatin in “stable disease” and progression between the treatment intervals. We performed maintenance “second-line” therapy for 24 cycles and the patient showed a remarkable persisting response 54 months after operation.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. Bannowsky, H. Ahlen and K. Jünemann, "Long Term Progression Free Survival Achieved by Maintenance “Second–Line” Polychemotherapy with Gemcitabine/Paclitaxel in Metastatic Urothelial Cancer of the Renal Pelvis—A Case Report," Journal of Cancer Therapy, Vol. 1 No. 4, 2010, pp. 229-231. doi: 10.4236/jct.2010.14035.

References

[1] S. Hauser and U. E. Studer , “Therapy of the Renal Pelvis Carcinoma,” Urologe [A], Vol. 40,No. 6, 2001, pp. 452-455.
[2] J. J. Munoz, L. M. Ellison, “Upper Tract Urothelial Neoplasms: Incidence and Survival during the Last 2 Decades,” Journal of Urology, Vol. 164, No. 5, 2000, pp. 1523-1525.
[3] C. N. Sternberg, “Metastatic Bladder Cancer: Role of Chemotherapy and New Agents,” EAU Update Series, Vol. 1, No. 2, 2003, pp. 108-117.
[4] J. Lehmann, M. Retz, M. Hack, S. Siemer and M. St?ckle, “Systemic Chemotherapy of Urothelial Cancer,” Onkologie, Vol. 26, suppl. 4, 2003, pp. 18-25.
[5] A. Bamias, C. Deliveliotis, G. Fountzilas, et al., “Adjuvant Chemotherapy with Paclitaxel and Carboplatin in Patients with Advanced Carcinoma of the Upper Urinary Tract: a study by the Hellenic Cooperative Oncology Group,” Journal of Clinical Oncology, Vol. 22, No. 11, 2004, pp. 2150-2154.
[6] S. Culine, C. Theodore, M. De Santis, et al., “A phase II study of Vinflunine in Bladder Cancer Patients Progressing after First-line Platinum-containing Regimen,” British Journal of Cancer, Vol. 94, 2006, pp. 1395-1401.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.